SEARCH

SEARCH BY CITATION

References

  • Aguilar JC & Rodriguez EG (2007) Vaccine adjuvants revisited. Vaccine 25: 37523762.
  • Akira S, Takeda K & Kaisho T (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408: 740745.
  • Alving CR (1993) Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 187: 430446.
  • Ballas ZK, Rasmussen WL & Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157: 18401845.
  • Bertok L (2005) Radio-detoxified endotoxin activates natural immunity: a review. Pathophysiology 12: 8595.
  • Cho YJ, Ahn BY, Lee NG, Lee DH & Kim DS (2006) A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. Vaccine 24: 58625871.
  • Cho YJ, Ahn BY, Song ES, Park SA, Lee DH, Kim DS & Lee NG (2007) Bacterial DNA containing methylated CpG motifs retains immunostimulatory activity in synergy with modified lipopolysaccharides. Microbiol Immunol 51: 211222.
  • Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW & Heathcote J (2004a) CpG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24: 693701.
  • Cooper CL, Davis HL, Morris ML et al. (2004b) Safety and immunogenicity of CpG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22: 31363143.
  • Cowdery JS, Chace JH, Yi AK & Krieg AM (1996) Bacterial DNA induces NK cells to produce interferon gamma in vivo and increases the toxicity of lipopolysaccharide. J Immunol 156: 45704575.
  • Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J & Krieg AM (1998) CpG DNA is potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160: 870876.
  • Di Pauli R (1972) Genetics of the immune response. I. Differences in the specificity of antibodies to lipopolysaccharides among different strains of mice. J Immunol 109: 394400.
  • Freidag BL, Melton GB, Collins F, Klinman DM, Cheever A, Stobie L, Suen W & Seder RA (2000) CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. Tuberculosis. Infect Immun 68: 29482953.
  • Gao JJ, Xue Q, Papasian CJ & Morrison DC (2001) Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol 166: 68556860.
  • Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S & Hartmann G (2002) Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169: 38923899.
  • Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709760.
  • Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA & Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546549.
  • Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97107.
  • Lee CH & Tsai CM (1999) Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal Biochem 267: 161168.
  • Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM & Whisnant JK (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64: 50745077.
  • Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF & Crooke ST (1997) Immune stimulation-a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 12: 421432.
  • Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R & Engelhardt R (1996) Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J cancer 32A: 17121718.
  • Pichyangkul S, Yongvanitchit K, Kum-arb U, Krieg AM, Heppner DG & Wals DS (2001) Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. J Immunol Methods 247: 8394.
  • Roberts TL, Dunn JA, Terry TD, Jennings MP, Hume DA, Sweet MJ & Stacey KJ (2005) Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J Immunol 175: 35693576.
  • Schirmbeck R, Wild J & Reimann J (1998) Similar as well as distinct MHC class-I binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur J Immunol 28: 41494161.
  • Shimada S, Yano O & Tokunaga T (1986) In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn J Cancer Res 77: 808816.
  • Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW & Wagner H (1998) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28: 20452054.
  • Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC & Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739746.
  • Stacey KJ & Blackwell JM (1999) Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 67: 37193726.
  • Stacy KJ, Sweet MJ & Hume DA (1996) Macrophages ingest and are activated by bacterial DNA. J Immunol 157: 21162122.
  • Weigel BJ, Rodeberg DA, Krieg AM & Blazar BR (2003) CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 9: 31053114.
  • Weiner GJ (2000) Immunostimulatory DNA sequences and cancer therapy. Springer Semin Immunopathol 22: 107116.
  • Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T & Tokunaga T (1992) DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36: 983997.